Promising effects of 3rd line cyclophosphamide, adriamycin and vincristine (CAV) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|6|5|659-663

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.6, Iss.5, 2015-09, pp. : 659-663

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice

By  

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 241-252

John Wiley & Sons Inc

Access to resources Recommend Favorite

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 175-180

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evolution of induction chemotherapy for non‐small cell lung cancer over the last 30 years: A surgical appraisal

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 731-740

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of chemotherapy for newly diagnosed advanced non‐small cell lung cancer with venous thromboembolism

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 772-777

John Wiley & Sons Inc

Access to resources Recommend Favorite

Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non‐small cell lung cancer patients

By  

Thoracic Cancer, Vol. 6, Iss. 5, 2015-09 ,pp. : 620-628

John Wiley & Sons Inc

Access to resources Recommend Favorite